Genetron(GTH) - 2021 Q2 - Quarterly Report

Genetron Health Announces Changes to the Board of Directors and Executive Officer Board of Directors Changes Genetron Health announced the appointment of Dr. Chao Tang and Mr. Shan Fu as new Directors, replacing Dr. Weiwu He and Mr. Weidong Liu who resigned for personal reasons, with co-founder Mr. Sizhen Wang appointed as the new Chairman and Dr. Weiwu He named Chairman Emeritus Summary of Board of Directors Changes | Role Change | Individual | Details | | :--- | :--- | :--- | | Appointment | Dr. Chao Tang | Appointed as Director | | Appointment | Mr. Shan Fu | Appointed as Director | | Appointment | Mr. Sizhen Wang | Appointed as new Chairman of the Board | | Resignation | Dr. Weiwu He | Resigned as Chairman of the Board; appointed Chairman Emeritus | | Resignation | Mr. Weidong Liu | Resigned as Director | - The company believes the new appointments will strengthen Genetron, citing Dr. Tang's expertise in interdisciplinary sciences and Mr. Fu's corporate board and global healthcare industry experience[4] Executive Officer Change Effective June 30, 2021, Mr. Kevin Ying Hong will resign as Chief Operating Officer (COO) for personal reasons, transitioning to the role of Senior Advisor to continue contributing his expertise to the company - Mr. Kevin Ying Hong will resign as COO for personal reasons, effective June 30, 2021, and will become a Senior Advisor to Genetron Health[4] Biographies of New Directors The new directors bring extensive experience from academia and the global healthcare industry, with Dr. Chao Tang specializing in physics and systems biology and Mr. Shan Fu in corporate finance and investment within the healthcare sector Dr. Chao Tang - Dr. Chao Tang is a Chair Professor of Physics and Systems Biology at Peking University, a Fellow of the American Physical Society, and an Academician of the Chinese Academy of Sciences, focusing his research on the interface between physics and biology[5] Mr. Shan Fu - Mr. Shan Fu has served as joint CEO of Vivo Capital LLC since October 2013 and previously was the Chief Representative of China at Blackstone Group, also serving as a Non-Executive Director for several other publicly listed healthcare companies, including TOT BIOPHARM, InnoCare Pharma, and Sinovac Biotech[6] Safe Harbor Statement - The announcement contains forward-looking statements as defined by the U.S. Private Securities Litigation Reform Act of 1995, which involve inherent risks and uncertainties, and the company cautions that actual results could differ materially from those projected without undertaking any duty to update this information[7]